Key result
Statin plus ezetimibe linked to ~90% target LDL-C achievement vs statin alone in ACS patients.
Why the study?
ESC recommends systematic screening of HbA1c and LDL-C following ACS, but adherence to these recommendations varies across centres.
Does dual lipid-lowering therapy improve the achievement of LDL-C targets compared to statin monotherapy in patients following acute coronary syndrome?
Population
144 ACS admissions at a University Hospital in the West of Ireland
Comparison
Treatment strategies including statin monotherapy vs dual therapy (statin + ezetimibe) vs no therapy
Design
Retrospective review
Follow-up
Median 9.6 weeks (IQR 6.1–16.2)
Authors
Loading...
Persistent LDL-C gaps after ACS warrant systematic follow-up; leaves open optimal real-world strategies in observational cohorts.
Cohort (n=144)
No
Does dual lipid-lowering therapy improve the achievement of LDL-C targets compared to statin monotherapy in patients following acute coronary syndrome?
Absolute Event Rate: 89.5% vs 44.2%
p-value: p=<0.01
Real-world data demonstrates that while initial post-ACS lipid screening is high, follow-up testing is underutilized, and dual lipid-lowering therapy is significantly more effective than statin monotherapy at achieving ESC LDL-C targets.
Farren et al. (2026) conducted a cohort in Acute coronary syndrome (ACS) (n=144). Dual therapy (statin + ezetimibe) vs. Statin monotherapy was evaluated on Achieving LDL-C targets (<1.4 mmol/L) at follow-up (p=<0.01). Among ACS patients, target LDL-C (<1.4 mmol/L) achievement at follow-up was 89.5% with dual therapy (statin + ezetimibe) and 44.2% with statin monotherapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: